- Home
- AAMI vs JANX Comparison
AAMI vs JANX Comparison
Compare AAMI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | JANX |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AAMI | JANX |
|---|---|---|
| Price | $47.77 | $13.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $45.00 | ★ $60.27 |
| AVG Volume (30 Days) | 224.7K | ★ 2.6M |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | ★ 45.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $559,300,000.00 | $10,000,000.00 |
| Revenue This Year | $17.23 | N/A |
| Revenue Next Year | $24.02 | N/A |
| P/E Ratio | $19.60 | ★ N/A |
| Revenue Growth | ★ 19.25 | N/A |
| 52 Week Low | $22.60 | $13.62 |
| 52 Week High | $54.99 | $61.59 |
Technical Indicators
Market Signals| Indicator | AAMI | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 26.70 |
| Support Level | $47.20 | $13.82 |
| Resistance Level | $49.00 | $14.49 |
| Average True Range (ATR) | 1.29 | 0.49 |
| MACD | -0.11 | 0.32 |
| Stochastic Oscillator | 46.79 | 4.60 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.